Overview

Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer

Status:
Terminated

Trial end date:
2017-11-01

Target enrollment:

Participant gender:

Summary

To determine the maximum-tolerated dose (MTD) of BKM120 when administered orally in combination with daily bicalutamide and LH-RH agonists to men with non castrate metastatic prostate cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Institut Paoli-Calmettes

Collaborator:

Novartis

Treatments:

Bicalutamide
Buserelin
Prolactin Release-Inhibiting Factors